ALT
Altimmune, Inc. NASDAQ Listed May 26, 2017$2.70
+2.27%
vs $2.64
Mkt Cap $237.9M
52w Low $2.59
2.1% of range
52w High $7.71
50d MA $2.96
200d MA $3.89
P/E (TTM)
-2.7x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.2x
ROE
-39.2%
P/FCF
-3.5x
RSI (14)
26.70
ATR (14)
$0.12
Beta
0.34
50d MA
$2.96
200d MA
$3.89
Avg Volume
3.2M
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
910 Clopper Road · Gaithersburg, MD 20878 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.25 | -0.18 | +28.0% | 3.08 | -3.2% | -1.9% | -3.3% | -2.4% | -1.8% | -2.1% | — |
| Mar 5, 2026 | BMO | -0.25 | -0.27 | -8.0% | 3.51 | +0.9% | +0.9% | +9.6% | -0.5% | -1.6% | -5.3% | — |
| Nov 6, 2025 | BMO | -0.29 | -0.21 | +27.6% | 3.94 | -0.5% | +4.3% | +3.6% | +0.5% | -1.2% | -4.0% | — |
| Aug 12, 2025 | BMO | -0.32 | -0.27 | +15.6% | 3.62 | +0.6% | +3.3% | -1.6% | -1.4% | -1.9% | +1.7% | — |
| May 13, 2025 | BMO | -0.35 | -0.26 | +25.7% | 5.76 | +0.5% | -1.0% | +1.4% | -3.5% | -1.4% | +6.4% | — |
| Feb 27, 2025 | BMO | -0.34 | -0.33 | +2.9% | 6.42 | -2.6% | +3.6% | -9.9% | -0.5% | -4.0% | -2.3% | — |
| Nov 12, 2024 | BMO | -0.36 | -0.32 | +11.1% | 9.49 | +2.7% | +0.3% | -11.1% | -10.0% | -6.0% | +4.5% | — |
| Aug 8, 2024 | BMO | -0.34 | -0.35 | -2.9% | 6.33 | +1.1% | -2.5% | +0.8% | +1.4% | -2.1% | +1.0% | — |
| May 9, 2024 | BMO | -0.36 | -0.34 | +5.6% | 7.72 | -0.9% | -6.5% | +2.1% | +6.1% | +13.4% | +0.3% | — |
| Mar 27, 2024 | BMO | -0.35 | -0.33 | +5.7% | 8.89 | +1.9% | +14.5% | +0.5% | -8.5% | -0.7% | -4.2% | — |
| Nov 7, 2023 | BMO | -0.40 | -0.39 | +2.5% | 2.70 | -0.4% | +0.0% | -9.3% | +2.0% | -2.4% | -1.2% | — |
| Aug 10, 2023 | BMO | -0.44 | -0.32 | +27.3% | 3.04 | +0.3% | -1.0% | -1.0% | -5.7% | -3.2% | -1.1% | — |
| May 11, 2023 | AMC | -0.49 | -0.40 | +18.4% | 5.33 | +1.1% | -4.5% | -4.7% | -4.1% | -1.1% | -3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Goldman Sachs | Upgrade | Sell → Neutral | $2 | $2.89 | $2.95 | +2.1% | -1.4% | -1.8% | -2.1% | -4.0% | -1.1% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.60 | +2.9% | +3.4% | -2.5% | -3.1% | +0.0% | -2.3% |
| Mar 6 | B. Riley Securities | Maintains | Buy → Buy | — | $3.51 | $3.54 | +0.9% | +0.9% | +9.6% | -0.5% | -1.6% | -5.3% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.94 | $3.92 | -0.5% | +4.3% | +3.6% | +0.5% | -1.2% | -4.0% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.83 | $3.87 | +1.0% | +4.4% | +1.0% | -3.5% | +1.5% | -0.3% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $4.03 | +0.8% | -2.0% | +2.0% | -0.8% | +0.8% | -2.8% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | -1.6% | -1.4% | -1.9% | +1.7% |
| Aug 13 | B. Riley Securities | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | -1.6% | -1.4% | -1.9% | +1.7% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | -1.6% | -1.4% | -1.9% | +1.7% |
| Jul 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.74 | $4.00 | -15.6% | -7.2% | -5.9% | +2.9% | -1.9% | +0.0% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.61 | $3.64 | +0.8% | -3.0% | +10.6% | +9.3% | +15.8% | -2.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.48 | -6.3% | -6.7% | -4.9% | -6.1% | -7.8% | +15.3% |
| Apr 2 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $4.75 | $4.67 | -1.7% | +0.6% | -6.7% | -4.9% | -6.1% | -7.8% |
| Mar 14 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.20 | $5.39 | +3.7% | +13.8% | +0.8% | -6.0% | +3.6% | -0.5% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.71 | +0.9% | -9.9% | -0.5% | -4.0% | -2.3% | -0.4% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.64 | $6.70 | +0.9% | +5.3% | -1.1% | -3.6% | -0.8% | -4.8% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.94 | $6.86 | -1.2% | +1.7% | -1.1% | +0.3% | -1.0% | +0.3% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $6.81 | -0.3% | +1.6% | +1.7% | -1.1% | +0.3% | -1.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $9.55 | +0.3% | -11.1% | -10.0% | -6.0% | +4.5% | +7.8% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $6.17 | $6.17 | +0.0% | +0.8% | +1.4% | -2.1% | +1.0% | +4.0% |
| Jun 25 | B. Riley Securities | Maintains | Buy → Buy | — | $7.14 | $7.11 | -0.4% | +3.8% | -15.5% | +2.1% | +4.1% | +8.3% |
| Jun 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.94 | $6.00 | +1.0% | +7.9% | +11.4% | +3.8% | -15.5% | +2.1% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.37 | $7.53 | +2.2% | +6.1% | +13.4% | +0.3% | -10.0% | +0.4% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.72 | $7.65 | -0.9% | -6.5% | +2.1% | +6.1% | +13.4% | +0.3% |
| Apr 29 | Guggenheim | Downgrade | Buy → Neutral | — | $7.26 | $6.86 | -5.5% | -11.8% | +2.3% | +7.9% | +1.7% | +1.5% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.18 | $10.25 | +0.7% | +0.5% | -8.5% | -0.7% | -4.2% | +2.1% |
| Mar 28 | B. Riley Securities | Maintains | Buy → Buy | — | $8.89 | $9.06 | +1.9% | +14.5% | +0.5% | -8.5% | -0.7% | -4.2% |
| Feb 13 | B. Riley Securities | Maintains | Buy → Buy | — | $10.40 | $9.88 | -5.0% | -18.7% | +6.5% | -0.7% | -2.1% | -4.1% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $5.74 | +81.6% | +13.0% | +29.7% | +11.7% | +33.1% | -4.4% |
| Nov 9 | B. Riley Securities | Maintains | Buy → Buy | — | $2.70 | $2.71 | +0.4% | -9.3% | +2.0% | -2.4% | -1.2% | +1.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.01 | +0.0% | -1.0% | -5.7% | -3.2% | -1.1% | -1.5% |
| Aug 11 | B. Riley Securities | Maintains | Buy → Buy | — | $3.04 | $3.05 | +0.3% | -1.0% | -1.0% | -5.7% | -3.2% | -1.1% |
| Jul 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.38 | $3.43 | +1.5% | -1.8% | +2.1% | -3.2% | -3.0% | -0.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.09 | $5.15 | +1.2% | -4.7% | -4.1% | -1.1% | -3.3% | +0.9% |
| Mar 31 | JMP Securities | Maintains | Market Outperform → Outperform | — | $4.22 | $4.21 | -0.2% | +0.0% | +4.7% | -6.8% | -6.1% | +3.6% |
| Mar 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $4.95 | $4.99 | +0.8% | -15.2% | -0.2% | +3.1% | +11.6% | -8.3% |
| Mar 22 | Goldman Sachs | Downgrade | Buy → Neutral | — | $4.95 | $4.99 | +0.8% | -15.2% | -0.2% | +3.1% | +11.6% | -8.3% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.05 | $11.08 | +0.3% | +2.9% | -8.8% | +4.0% | +2.9% | -1.4% |
| Feb 6 | JMP Securities | Maintains | Market Outperform → Outperform | — | $15.16 | $15.10 | -0.4% | +0.5% | -0.4% | -8.7% | +1.3% | -4.3% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.96 | $14.96 | +0.0% | -4.1% | +1.5% | -2.8% | -0.9% | -0.9% |
| Jan 18 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.96 | $15.26 | +2.0% | +0.1% | -0.1% | -4.1% | +1.5% | -2.8% |
| Dec 1 | Goldman Sachs | Maintains | Buy → Buy | — | $9.95 | $10.80 | +8.5% | +8.4% | +4.5% | -2.0% | -6.9% | -0.7% |
| Nov 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $10.58 | $10.35 | -2.2% | +1.0% | -0.9% | +3.1% | -12.6% | -7.9% |
| Sep 16 | Guggenheim | Maintains | Buy → Buy | — | $14.39 | $14.22 | -1.2% | -5.0% | -6.2% | -1.7% | +0.7% | +5.2% |
| Aug 31 | Jefferies | Maintains | Buy → Buy | — | $18.94 | $19.20 | +1.4% | +16.6% | -1.1% | +2.7% | -5.8% | -4.2% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.66 | $17.87 | +1.2% | -2.7% | +5.3% | -5.2% | +3.1% | +4.1% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $13.77 | $13.80 | +0.2% | +26.1% | +1.0% | +0.7% | -2.7% | +5.3% |
| May 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.29 | $5.13 | -3.0% | -8.5% | -0.4% | +4.1% | -3.4% | -2.7% |
| Jun 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $15.90 | $10.71 | -32.6% | -38.1% | +1.9% | -7.0% | -5.0% | -5.0% |
| Jun 30 | B. Riley Securities | Maintains | Buy → Buy | — | $15.90 | $10.71 | -32.6% | -38.1% | +1.9% | -7.0% | -5.0% | -5.0% |
No insider trades available.
8-K · 2.02
!! High
Altimmune, Inc. -- 8-K 2.02: Earnings Results
Altimmune reported financial results on May 13, 2026, though specific performance metrics and operational outcomes are not detailed in this filing summary.
May 13
8-K
Altimmune, Inc. -- 8-K Filing
Altimmune's capital raise will fund its Phase 3 trial for pemvidutide in MASH and pre-commercial activities, providing runway to advance its lead metabolic disease program.
Apr 24
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Altimmune increased authorized shares, enabling potential dilution for future fundraising or acquisitions, which could pressure existing shareholders' ownership percentages and earnings per share.
Apr 16
8-K
Altimmune, Inc. -- 8-K Filing
Altimmune reports full-year 2025 results and reaffirms its late-stage development focus on pemvidutide for metabolic dysfunction-associated fatty liver disease, positioning the candidate as a differentiated treatment option for serious liver conditions.
Mar 5
8-K · 8.01
!! High
Altimmune, Inc. -- 8-K 8.01: Material Event / Announcement
Altimmune scheduled its 2026 Annual Meeting for April 16, 2026, with a March 13 record date, allowing shareholders to vote on corporate matters.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 5,658,049 | $17M | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 5,382,002 | $17M | New | Mar 2026 |
| 3 | Marshall Wace, Llp | 4,017,901 | $12M | Added | Mar 2026 |
| 4 | Millennium Management | 3,258,191 | $10M | Added | Mar 2026 |
| 5 | Morgan Stanley | 2,719,770 | $10M | Reduced | Dec 2025 |
| 6 | Alyeska Investment Group, L.p. | 2,644,600 | $8M | New | Mar 2026 |
| 7 | Tang Capital Management Llc | 2,131,307 | $8M | — | Dec 2025 |
| 8 | Two Sigma Investments, Lp | 2,478,900 | $8M | Added | Mar 2026 |
| 9 | Nuveen, Llc | 2,334,601 | $7M | Added | Mar 2026 |
| 10 | Jane Street Group, Llc | 1,783,950 | $6M | Added | Dec 2025 |
| 11 | Susquehanna International Group, Llp | 1,325,956 | $4M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 996,721 | $3M | Added | Mar 2026 |
| 13 | Ubs Group Ag | 904,768 | $3M | Added | Mar 2026 |
| 14 | D.e. Shaw & Co | 727,001 | $2M | Reduced | Mar 2026 |
| 15 | Fmr Llc | 673,964 | $2M | Added | Mar 2026 |
| 16 | Point72 Asset Management | 665,289 | $2M | New | Mar 2026 |
| 17 | Schroder Investment Management Group | 667,837 | $2M | Added | Mar 2026 |
| 18 | Bank Of America Corp /de/ | 570,203 | $2M | Added | Mar 2026 |
| 19 | Citadel Advisors Llc | 448,873 | $1M | Reduced | Mar 2026 |
| 20 | Beirne Wealth Consulting Services, Llc | 376,458 | $1M | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$237.9M
Enterprise Value
-$1.3M
P/E (TTM)
-2.70x
Forward P/E
—
PEG Ratio
0.14x
P/B
1.06x
P/S
5801.98x
P/FCF
-3.52x
EV/EBITDA
—
Shares Out
88.1M
Financials (TTM)
Revenue
$41K
Net Income
-$88.1M
EBITDA
-$94.5M
Free Cash Flow
-$67.5M
Op Cash Flow
-$67.5M
EPS Basic
$-1.00
EPS Diluted
$-1.00
EPS Forward
$-1.06
Gross Margin
-173.2%
Op Margin
-230461.0%
Net Margin
-214861.0%
Balance Sheet
Total Assets
$279.9M
Total Liab.
$55.0M
Total Equity
$224.9M
Cash
$273.5M
LT Debt
$34.3M
Book Value/Sh
$2.55
Debt/Equity
0.16x
Current Ratio
18.55
Quick Ratio
18.55
Returns & Growth
ROE
-39.2%
ROA
-31.5%
ROIC
-35.4%
Rev Growth YoY
+105.0%
EPS Growth YoY
+25.4%
Price Returns
2W
+4.5%
1M
+17.3%
3M
-29.2%
6M
-42.0%
12M
-43.8%
Technicals
52W High
$7.71
52W Low
$2.59
50d MA
$2.96
200d MA
$3.89
RSI (14)
26.70
ATR (14)
$0.12
Beta
0.34
Avg Volume
3.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.25
High
$20.00
Low
$2.50
Median
$11.25
Data updated apr 24, 2026 5:32pm
· Source: financialmodelingprep.com